Human African Trypanosomiasis: Progress and Stagnation.
Infect Dis Clin North Am
; 33(1): 61-77, 2019 03.
Article
em En
| MEDLINE
| ID: mdl-30712768
ABSTRACT
Control efforts have considerably reduced the prevalence of human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in West/Central Africa and to Trypanosoma brucei rhodesiense in East Africa. Management of T brucei gambiense HAT has recently improved, with new antibody-based rapid diagnostic tests suited for mass screening and clinical care, and simpler treatments, including the nifurtimox-eflornithine combination therapy and the new oral drug fexinidazole to treat the second stage of the disease. In contrast, no major advance has been achieved for the treatment of T brucei rhodesiense HAT, a zoonosis that occasionally affects short-term travelers to endemic areas.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tripanossomíase Africana
/
Antiprotozoários
Tipo de estudo:
Prevalence_studies
/
Risk_factors_studies
/
Screening_studies
Limite:
Animals
/
Humans
País/Região como assunto:
Africa
Idioma:
En
Revista:
Infect Dis Clin North Am
Assunto da revista:
DOENCAS TRANSMISSIVEIS
Ano de publicação:
2019
Tipo de documento:
Article